The Small Animal Cancer Imaging Research Facility (SACIRF) provides cancer investigators with the latest technology and techniques for experimental in vivo imaging of small animals. The facility includes state-ofthe- art instrumentation, including the modalities of magnetic resonance (MR, Bruker4.7 T, 40 cm Biospec), x-ray computed tomography (micro-CT from Enhanced Vision Systems and volume CT being developed in collaboration with General Electric), projection radiography (Faxitron), and nuclear imaging (M.Cam gamma camera from Siemens and micro-PET from Concorde Microsystems). Optical imaging will be added during the first year of the award (instrumentation to be developed in collaboration with Biomedical Engineering at The University of Texas-Austin). This instrumentation represents a >$3M investment by MDACC. The SACIRF has allocated space for the instruments in the animal support facilities to facilitate the inclusion of the imaging studies in ongoing cancer research, and dedicated office and developmental laboratory space to support the facility operation. The faculty and staff are well-qualified in each of the modality areas, including current image acquisition and image analysis techniques. Specialty areas include quantitative tissue characterization (MR), imaging of microvascular physiology (MR, nuclear, CT and optical), diffusion imaging for estimating cellular density (MR), metabolic imaging (nuclear, positron emission tomography [PET], optical and MR spectroscopy), and vascular imaging (MR, CT, and x-ray). The services of the facility include imaging protocol design, custom positioning systems, custom data acquisition hardware and software, image analysis, data archiving, provision of hardcopy and digital data delivery, and database maintenance. The Veterinary Core includes a dedicated support team that provides highly efficient imaging studies and a very low mortality rate of animals during the imaging procedures. Services provided from the Veterinary Core include development of veterinary support protocols specific to each experimental design, and consultation on the inclusion of imaging procedures into existing protocols to obtain Institutional Animal Care and Use Committee approval. To date, 75 investigators representing 13 programs have used facility instrumentation. 42% of the users are peer-review-funded investigators. Utilization continues to increase as the facility and its capabilities become better known to the local cancer research community. The capabilities of the facility continue to grow to meet experimental demands. Publications are evolving at a rapid pace, and although only a few are published, the acceptance rate has been nearly 100%. Funding for the SACIRF is currently CCSG (43%), user fees (36%), and MDACC (21%).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-37
Application #
8379465
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
37
Fiscal Year
2012
Total Cost
$236,872
Indirect Cost
$83,063
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Garg, Rachana; Blando, Jorge M; Perez, Carlos J et al. (2018) COX-2 mediates pro-tumorigenic effects of PKC? in prostate cancer. Oncogene 37:4735-4749
Flinn, Ian W; O'Brien, Susan; Kahl, Brad et al. (2018) Duvelisib, a novel oral dual inhibitor of PI3K-?,?, is clinically active in advanced hematologic malignancies. Blood 131:877-887
Subbiah, Ishwaria M; Tang, Chad; Rao, Arvind et al. (2018) Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget 9:28842-28848
Daver, Naval; Boddu, Prajwal; Garcia-Manero, Guillermo et al. (2018) Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia 32:1094-1105
Bailey, Matthew H; Tokheim, Collin; Porta-Pardo, Eduard et al. (2018) Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell 173:371-385.e18
Ohri, Nisha; Sittig, Mark P; Tsai, Chiaojung Jillian et al. (2018) Trends and variations in postmastectomy radiation therapy for breast cancer in patients with 1 to 3 positive lymph nodes: A National Cancer Data Base analysis. Cancer 124:482-490
Cao, Qizhen; Yan, Xinrui; Chen, Kai et al. (2018) Macrophages as a potential tumor-microenvironment target for noninvasive imaging of early response to anticancer therapy. Biomaterials 152:63-76
Vichaya, Elisabeth G; Dantzer, Robert (2018) Inflammation-induced motivational changes: Perspective gained by evaluating positive and negative valence systems. Curr Opin Behav Sci 22:90-95
Nguyen, Jennifer; Jiao, Jingjing; Smoot, Kristin et al. (2018) Toll-like receptor 4: a target for chemoprevention of hepatocellular carcinoma in obesity and steatohepatitis. Oncotarget 9:29495-29507
Reddy, S M; Barcenas, C H; Sinha, A K et al. (2018) Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. Br J Cancer 118:17-23

Showing the most recent 10 out of 12418 publications